Condition: Type 2 Diabetes Mellitus (T2DM) · Sponsor: Alnylam Pharmaceuticals
The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
This description comes directly from the study's public registry record.
Alnylam Clinical Trial Information Line · 1-877-ALNYLAM · clinicaltrials@alnylam.com
Alnylam Clinical Trial Information Line · 1-877-256-9526 · clinicaltrials@alnylam.com
Always discuss trial participation with your own doctor first.
| Clinical Trial Site | Chula Vista, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07465224